RSV
Conditions
Interventions
The volunteer will receive a single dose of 500 mg radiolabeled JNJ-53718678 as
an oral solution (50 milliliter).
Sponsors
Janssen Sciences Ireland UC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - healthy male subjects - 18 - 55 yrs, inclusive - BMI: 18.0 to 30.0 kg/m2, extremes included
Exclusion criteria
Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. Subject has received an experimental drug or experimental vaccine, or has used an experimental medical device within 1 month or within a period less than 10 times the drug*s half-life, whichever is longer, before scheduled study drug administration. Subject has donated blood or blood products or has had substantial loss of blood within 3 months before study drug administration or intention to donate blood or blood products during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - to determine the routes of excretion for JNJ-53718678 and its metabolites after administration of a single oral dose of 14C-JNJ-53718678 in healthy adult male subjects - to explore the metabolic pathways of JNJ-53718678 after administration of a single oral dose of 14C-JNJ-53718678 in healthy adult male subjects - to determine the chemical structure of predominant metabolites | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine safety and tolerability of a single oral dose of 14CJNJ- 53718678 in healthy adult male subjects. | — |
Countries
Netherlands
Outcome results
None listed